SBIR Phase I: An Injectable Treatment for the Repair of Damaged Tendons and Ligaments
- Funded by National Science Foundation (NSF)
- Total publications:0 publications
Grant number: 2026007
Grant search
Key facts
Disease
COVID-19Start & end year
20202021Known Financial Commitments (USD)
$255,947Funder
National Science Foundation (NSF)Principal Investigator
Adam HackingResearch Location
United States of AmericaLead Research Institution
RegenX LLCResearch Priority Alignment
N/A
Research Category
Vaccines research, development and implementation
Research Subcategory
Pre-clinical studies
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to develop safe and affordable COVID-19 vaccination technology, with broader utility in preventing other types of outbreak in the future. This novel vaccination platform is based on modifying bacteria, long used as a cost-effective, safe vaccine for pediatric tuberculosis immunization. The novel vaccine is anticipated to show heat-stability, safety, cost-effectiveness, and ease of mass production. It may be employed for pediatric immunizations and for other at-risk groups, including first responders, the elderly, and those with underlying chronic conditions. In addition, this can be used in emerging and disadvantaged communities.
The proposed project enables a novel microbial vaccine platform based on recombinant BCG bacteria (rBCG) engineered to target SARS-CoV-2, with the potential to protect against COVID-19 disease. This new design addresses the potential limitation of a lack of specificity to SARS-CoV-2. Preliminary results demonstrate that the integration and the expression of foreign genes can be successfully achieved in BCG bacteria. This project will develop BCG that expresses SARS-CoV-2 protein fragments, which could lead to the induction of appropriate immune responses against SARS-CoV-2 specific antigens. New rBCG candidates with the highest secretion and durable expression levels of viral polypeptides will be selected and prioritized based on their biological properties. The rBCG vaccines will be evaluated for safety and immunogenicity in animal models. Promising vaccine candidates that show no adverse events and induce robust T-cell and antibody responses will be selected for future studies.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
The proposed project enables a novel microbial vaccine platform based on recombinant BCG bacteria (rBCG) engineered to target SARS-CoV-2, with the potential to protect against COVID-19 disease. This new design addresses the potential limitation of a lack of specificity to SARS-CoV-2. Preliminary results demonstrate that the integration and the expression of foreign genes can be successfully achieved in BCG bacteria. This project will develop BCG that expresses SARS-CoV-2 protein fragments, which could lead to the induction of appropriate immune responses against SARS-CoV-2 specific antigens. New rBCG candidates with the highest secretion and durable expression levels of viral polypeptides will be selected and prioritized based on their biological properties. The rBCG vaccines will be evaluated for safety and immunogenicity in animal models. Promising vaccine candidates that show no adverse events and induce robust T-cell and antibody responses will be selected for future studies.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.